
Opinion|Videos|October 7, 2024
ECOSPOR Trials and Data with Fecal Microbiota Spores, Live-BRPK Oral Capsules (VAS) for C. difficile Infections
Paul Feuerstadt, MD, FACG, AGAF, discusses the key findings from the phase 3 ECOSPOR clinical trial for fecal microbiota spores, live-brpk oral capsules (VAS).
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Discussion of key findings from the phase 3 clinical trial for fecal microbiota spores, live-brpk oral capsules (VAS).
- Comparing the two clinical trials, what were some significant differences between them?
Newsletter
Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Contagion Live
1
Measles Update: February 6, 2026
2
Pritelivir Improves Outcomes in Immunocompromised Patients With Refractory Herpes Simplex Virus
3
HIV in the Black Community: Shifting from Stigma and Health Inequalities to Communication and Care Initiatives
4
Antibiotics Deconstructed: IV Fosfomycin
5


































































































































